IL1A and rheumatoid arthritis: JAK inhibitors (JAK-i) inhibit the JAK-STAT pathway activity, and since many cytokine receptors, including IL-6, IFN type 1, IL-1, IL-17 and GM-CSF, signal through JAKs, they can be used to block cytokine signaling which is beneficial in the treatment of RA [154].